Does Scripps Health Cover Eliquis? A Woman's Guide to Insurance, Access, and Safe Use

What Scripps Health Coverage Actually Means for Eliquis

Scripps Health is a San Diego-based health system, not a standalone insurance carrier. That distinction matters. When people ask whether "Scripps Health covers Eliquis," they are usually asking one of two separate questions: does Scripps Coastal Medical or another Scripps-affiliated clinic accept their existing insurance plan for Eliquis prescriptions, or does a Scripps-branded health plan (such as those offered through Sharp Health Plan or other regional payers that contract with Scripps providers) include apixaban on the formulary?

Your coverage is determined by your insurer's formulary, not by the Scripps Health system itself. Scripps providers can prescribe Eliquis; whether your plan pays for it is your insurer's call.

How Formulary Tiers Work

Most commercial health plans in California organize drugs into four or five tiers. Generic drugs sit on Tier 1 or Tier 2. Brand-name drugs with no generic equivalent, like Eliquis (apixaban does not yet have an FDA-approved generic widely available in the US as of early 2025), typically land on Tier 3 or higher. The FDA's drug approval database lists currently approved apixaban products, and as of the date of this article, no AB-rated generic apixaban has reached widespread commercial distribution.

A Tier 3 placement usually means a copay of $47 to $100 for a 30-day supply. Tier 4 specialty placement can push that figure above $150. Your specific plan's Summary of Benefits and Coverage (SBC) document, available through your insurer's member portal, is the only authoritative source for your exact copay.

Steps to Verify Your Specific Coverage

1. Log in to your insurer's member portal and search "apixaban" or "Eliquis" in the formulary lookup tool.
2. Note the tier, any quantity limits, and whether prior authorization is required.
3. Call the pharmacy benefits number on the back of your insurance card. Ask specifically: "Is apixaban on my formulary, what tier, and does it require prior authorization for my diagnosis?"
4. Ask your Scripps-affiliated prescriber's office to submit a prior authorization if the plan requires one. Scripps medical offices are experienced with this process.
5. If denied, ask about the appeals process and your right to a step-therapy exception, particularly if your prescriber has documented a clinical reason you cannot use warfarin.

Why Women Pay Attention to Eliquis Differently Than Men Do

Eliquis is approved by the FDA for several indications, including reducing stroke risk in nonvalvular atrial fibrillation, treating and preventing recurrence of deep vein thrombosis (DVT) and pulmonary embolism (PE), and preventing VTE after hip or knee replacement surgery. The FDA prescribing information for Eliquis covers all approved uses.

Women's cardiovascular and clotting physiology is not the same as men's. Hormonal fluctuations across the menstrual cycle alter coagulation factor levels. Estrogen, whether endogenous or from oral contraceptives or hormone therapy, activates the coagulation cascade. A 2014 analysis published in Blood found that combined oral contraceptive use raises VTE risk approximately 3 to 9 times above baseline depending on progestin type, with desogestrel- and drospirenone-containing pills carrying higher risk than levonorgestrel formulations.

That elevated baseline risk is clinically relevant when your cardiologist or hematologist decides whether you need an anticoagulant, how long you need one, and how to monitor you.

Atrial Fibrillation in Women: Underdiagnosed and Undertreated

Women with atrial fibrillation are prescribed anticoagulants at lower rates than men, even after controlling for stroke risk score. A 2020 study in JAMA Cardiology documented this gap and found that women with AF had higher stroke rates partly because of lower anticoagulation use. Sex is an independent risk factor in the CHA2DS2-VASc scoring system used to guide anticoagulation decisions: simply being female adds one point to your score. That point matters. A CHA2DS2-VASc score of 2 or higher generally triggers an anticoagulation recommendation, and for many women, the female sex point alone combined with one other risk factor crosses that threshold.

If you have been told you have AF and have not been offered an anticoagulant conversation, ask your Scripps cardiologist directly whether your CHA2DS2-VASc score warrants one.

PCOS, Insulin Resistance, and Clot Risk

Polycystic ovary syndrome affects approximately 8 to 13 percent of reproductive-age women globally, according to WHO data. The metabolic features of PCOS, particularly insulin resistance and chronic low-grade inflammation, are associated with prothrombotic changes in coagulation factors. Women with PCOS who also take combined oral contraceptives for cycle regulation carry a compounded VTE risk. If you have PCOS and a history of DVT or PE, your prescriber should discuss whether long-term anticoagulation is appropriate and which agent fits your situation.

Eliquis Dosing in Women: What the Prescribing Information Says

Standard Eliquis dosing for the most common indications is as follows. For nonvalvular AF stroke prevention, the standard dose is 5 mg orally twice daily. The dose is reduced to 2.5 mg twice daily if you meet at least two of three criteria: age 80 or older, body weight 60 kg or less, or serum creatinine 1.5 mg/dL or higher. For acute DVT or PE treatment, the dose is 10 mg twice daily for 7 days, then 5 mg twice daily. For VTE prevention after orthopedic surgery, it is 2.5 mg twice daily.

Women with lower body weight are more likely to meet the dose-reduction criteria. Body weight at or below 60 kg is a threshold criterion, and women on average have lower body weight than men in clinical trial populations. If you are a petite woman on the standard 5 mg dose, confirm with your prescriber whether your renal function and weight have been factored in.

Renal Function Monitoring

Apixaban is approximately 27 percent renally eliminated. Women experience age-related decline in glomerular filtration rate (GFR) that may be masked by lower muscle mass, meaning serum creatinine can appear normal even when actual kidney function has declined. An estimated GFR (eGFR) calculation using CKD-EPI is more informative than creatinine alone. Ask your Scripps provider to include eGFR when reviewing whether your Eliquis dose needs adjustment.

Pregnancy and Lactation: A Required Conversation Before You Fill That Prescription

Eliquis is contraindicated in pregnancy. This is not a soft warning. Apixaban crosses the placenta and has the potential to cause fetal bleeding. Animal reproduction studies showed fetal toxicity. The FDA prescribing information carries no established human safety data for use in pregnant women, and the drug is classified as causing potential fetal harm. ACOG guidance on anticoagulation in pregnancy, available through acog.org, recommends low-molecular-weight heparin (LMWH) such as enoxaparin as the first-line anticoagulant throughout pregnancy because it does not cross the placenta.

If you are of reproductive age and prescribed Eliquis, your prescriber should discuss contraception with you before you start. Because combined hormonal contraceptives themselves raise VTE risk, an intrauterine device (hormonal or copper) or progestin-only methods may be safer choices than combined pills for women already on anticoagulation. This is a nuanced conversation that deserves time at your Scripps appointment.

If You Discover You Are Pregnant While Taking Eliquis

Stop Eliquis and contact your prescriber the same day. Do not wait for your next scheduled appointment. Your care team will transition you to LMWH promptly. The transition plan will depend on your underlying indication: women anticoagulated for AF face different pregnancy management considerations than women anticoagulated for a provoked DVT.

Breastfeeding and Apixaban

The prescribing information states that it is unknown whether apixaban is excreted in human breast milk. Because of the potential for serious adverse effects, including bleeding in a nursing infant, breastfeeding is not recommended while taking Eliquis. Women who require anticoagulation postpartum and wish to breastfeed should ask about LMWH or warfarin, both of which have more established lactation safety data. A Cochrane review on anticoagulants in lactating women is a resource your prescriber can consult.

Postpartum VTE Risk

The postpartum period carries 4 to 5 times higher VTE risk than the general population, with risk highest in the first 6 weeks after delivery. If you need anticoagulation initiated postpartum, LMWH is typically used for the first 6 weeks before transitioning to an oral agent. The transition timing and choice of oral anticoagulant should weigh your breastfeeding plans.

Perimenopause, Menopause, and Anticoagulation

Perimenopause is not a simple estrogen-withdrawal state. The transition typically spans 4 to 10 years and involves erratic estrogen surges alongside progesterone decline. Heavy menstrual bleeding (HMB) affects up to 25 percent of perimenopausal women, according to data cited in The Menopause Society's position statements. Starting an anticoagulant during this period can worsen HMB significantly, sometimes to the point of iron-deficiency anemia.

If you are perimenopausal and starting Eliquis, tell your prescriber about your cycle pattern before you fill the prescription. Options include cycle tracking, a baseline hemoglobin check, and possibly a discussion about whether a levonorgestrel IUD (Mirena) might reduce bleeding while not substantially elevating your clot risk the way combined pills would.

Hormone Therapy and Anticoagulation

Oral estrogen-containing hormone therapy raises VTE risk through hepatic first-pass effects on clotting factors. Transdermal estradiol does not carry the same thrombotic signal. The ESTHER study, published in BMJ, found that oral but not transdermal estrogen was associated with increased VTE risk. If you have AF or a history of VTE and need menopause hormone therapy, transdermal delivery is the safer route, and this should be part of your conversation with your Scripps gynecologist and cardiologist together.

Reducing What You Pay for Eliquis at Scripps Pharmacies

Manufacturer Patient Assistance

Bristol Myers Squibb and Pfizer offer a savings program for commercially insured patients. Eligible patients can pay as little as $10 per month for Eliquis. The program is not available to patients enrolled in Medicare, Medicaid, or other federal or state health programs. Visit the manufacturer's program site or ask your Scripps pharmacy about current eligibility requirements.

Prior Authorization and Step Therapy

If your Scripps-affiliated plan requires prior authorization, your prescriber must document the clinical indication. For step-therapy plans, the insurer may require a trial of warfarin first. California law under AB 374 (the Step Therapy Law) allows patients to request an exception to step therapy when a prescriber documents that the required first-step drug is clinically inappropriate. Your Scripps provider can submit that documentation.

90-Day Supply and Mail Order

A 90-day mail-order supply often costs less per pill than three separate 30-day fills at a retail pharmacy. Ask your insurer whether Eliquis is available through their preferred mail-order pharmacy at a lower tier copay. Scripps-affiliated providers can send a 90-day prescription directly.

GoodRx and Cash Pay Options

GoodRx prices for a 30-day supply of Eliquis 5 mg (60 tablets) fluctuate but have ranged from $450 to $550 at major San Diego-area pharmacies in early 2025. For most women, this is higher than using insurance, but for those whose plans exclude Eliquis entirely, a cash-pay coupon may be the only short-term bridge while a prior authorization appeal is pending.

Who This Medication Is Right For, and Who Should Reconsider

Women Who Are Typically Good Candidates for Eliquis

Eliquis may be a good fit for you if you have nonvalvular AF and a CHA2DS2-VASc score of 2 or higher, you have had a DVT or PE and need treatment or secondary prevention, you are postmenopausal or post-surgical without pregnancy plans, you have had a previous adverse event on warfarin such as difficult INR management or significant drug interactions, or you have been told warfarin is poorly suited to your lifestyle or genetics (CYP2C9 or VKORC1 variants affect warfarin metabolism and are more prevalent in some populations).

Women Who Should Discuss Alternatives First

Apixaban may not be the right first choice if you are pregnant (contraindicated), actively trying to conceive, breastfeeding a newborn, in late-stage chronic kidney disease (severe renal impairment, creatinine clearance <15 mL/min, is not well studied), or managing heavy menstrual bleeding that is already causing anemia. Women with mechanical heart valves should not use any direct oral anticoagulant; warfarin remains the standard for valvular AF.

Talking to Your Scripps Provider: Questions to Bring to Your Appointment

Preparing specific questions before your appointment improves the quality of the conversation and increases the chance your prescriber addresses the female-specific factors that can be missed in a short visit.

Ask: "What is my CHA2DS2-VASc score, and does my being a woman change the anticoagulation threshold for me specifically?" Ask: "My plan may require prior authorization. Can your office start that today?" Ask: "I am perimenopausal and have heavier periods than I used to. How do we monitor that if I start Eliquis?" Ask: "I am on a combined oral contraceptive for PCOS management. Should we switch methods given the additive clot risk?" Ask about the manufacturer savings card and whether the pharmacy at your Scripps clinic can apply it directly.

A NAMS-certified menopause practitioner on the WomanRx clinical editorial board put it plainly: "I see women started on oral anticoagulants without any conversation about their menstrual cycle or their hormone therapy route. Those two things can determine whether a woman ends up in the ER with a hemorrhagic period six weeks in. The drug choice is step one; the sex-specific management plan is step one-A."

What to Do If Scripps or Your Insurer Denies Coverage

A denial is not the end of the road. Your plan must provide a written denial with a reason code. Common reasons include non-formulary status, prior authorization not on file, or step-therapy requirements not met.

Your rights in California include the right to an internal appeal within 60 days of the denial, the right to an independent medical review (IMR) through the California Department of Managed Health Care (DMHC) if the internal appeal is denied, and the right to a step-therapy exception when your prescriber documents medical necessity.

The DMHC's Help Center at dmhc.ca.gov handles complaints and IMR requests. Approximately 40 percent of IMR cases in California result in decisions favorable to the patient. Document every call, every denial letter, and every prescriber note supporting your case.